In 3-5 years, Piramal Pharma can see 22- 25% EBITDA growth margins: Nandini Piramal

May 14, 2024

Nandini Piramal projects early teens revenue growth for FY25 and 22-25% EBITDA growth margins in 3-5 years. Revenue increase drives margin expansion through cost optimization and operational excellence, with a focus on CDMO and Indian consumer products growth.

More To Explore

US SEC yet to serve legal documents to Gautam Adani, his nephew in alleged $265 million bribery case

The US SEC is actively working to serve legal documents to Gautam Adani and his nephew Sagar in India, concerning a securities case filed in

June 27, 2025

Parag Parikh Flexi Cap Fund, Quant Small Cap Fund among 17 mutual funds which deliver over 20% XIRR on SIP investments in 10 years

Seventeen equity mutual funds delivered over 20% XIRR on SIPs over the past 10 years, led by Quant and Nippon India Small Cap Funds. Among

June 27, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003